Biomarker-driven treatment for muscle-invasive bladder cancer (MIBC) led to a 2-year metastasis-free survival (MFS) rate that ...

American Urological Association (AUA) annual meeting in San Antonio strongly emphasized diversity, equity, and inclusion, as ...

VMPL Chennai Tamil Nadu [India] December 23 Kauvery Hospital Vadapalani a leading healthcare institution in Chennai has ...

In 2022, over 600,000 people across the world were diagnosed with bladder cancer, a 7.1% increase from 2020, putting their ...

Treatment with UGN-102 has shown promise as a non-surgical alternative when compared with a surgical approach for certain ...

Although the use of intravesical immunotherapy for reducing tumor progression or as maintenance therapy is controversial, bacillus Calmette–Guérin has demonstrated significant benefit for tumor ...

(UroToday.com) The 2024 SUO annual meeting included a session on BCG unresponsive non muscle invasive bladder cancer (NMIBC), ...

(Nasdaq: ENGN, "enGene" or the "Company"), a clinical-stage genetic medicines company whose non-viral, intravesical lead product candidate, EG-70, is in a pivotal study for BCG-unresponsive high ...

ImmunityBio is conducting trials of Anktiva in various cancers, including NSCLC and ovarian cancer. Click here to read an analysis of IBRX stock now.

The first target for this plasmid is non-muscle invasive bladder cancer (NMIBC), which is currently managed primarily with ...

The trial is assessing intravesical TARA-002, the Company's investigational cell-based therapy, in high-risk Non-Muscle ...

The clinical-stage company said that patients in the intravesical trial studying its investigational cell-based therapy TARA-002 to treat non-muscle invasive bladder cancer have shown high complete ...